Ref # | Year of HT/Country | Gender/Age at HT (years) | Indication for HT | ARV regimen after HT | Routine immunosuppression regimen | Rejection/Grade | Follow-up (months) | Post-HT AIDS-defining illness | Post-HT viral load (copies/ml)/CD4 + count (cells/µl) | Drug interaction/Interacting drugs | Patient Status at last follow-up |
---|---|---|---|---|---|---|---|---|---|---|---|
[17]1 | 1997/USA | F/>40 | Non-ischemic CM | ZDV/3TC/EFV | CYA/MMF/P | Yes/3A and 1 A 2 | 120 | No | < 50/>200 | NR | Alive |
[18] | 2001/USA | M/39 | daunorubicin associated CM | ZDV/3TC/RTV | CYA/P/MMF or AZA | Yes/2-3 A 2 | 24 | No | < 50/multiple episodes of < 200 | Yes/CYA and RTV | Alive |
[19] | 2001/USA | M/42 | Idiopathic CM | TDF/3TC/NVP | NR | Yes/2 2 | 24 | No | < 50/650–1000 | NR | Alive |
[20]3 | 2001–2008/USA | 6 M and 1 F/19–48 | Dilated CM | NR | CYA/MMF/P | Yes/1B-3 A 2 | 3–88 (mean of 30) | No | UD/>200 (mean of 554 ± 169) | Yes/CYA and HAART | Alive |
[21] | 2007/Spain | M/39 | Ischemic CM | ZDV/3TC/ABC | FK/MMF/MP | Yes/3A 2 | 36 | No | < 50/201–754 | No | Alive |
[22]1 | 2007/USA | M/>60 | Ischemic CM | TDF/ FTC/EFV | FK/MMF/P | Yes/moderate | 34 | No | UD/50 at 30-month | NR | Dead |
[23] | 2008/France | M/32 | Dilated CM | ZDV/3TC/RAL/enfuvirtide | NR | Yes/2R 4 | 30 | No | UD/1,560 at 30-month | No | Alive |
[24] | 2008/USA | M/47 | Non-ischemic dilated CM | NR | NR | No | 31 | No | NR | NR | Alive |
[25] | 2009/USA | F/42 | Non-ischemic dilated CM | NR | FK/MMF/P | Yes/NR | 24 | No | NR | No | Alive |
[26] | 2009/Italy | M/36 | Non-ischemic dilated CM | ZDV/3TC/EFV | CYA/EVR/MP | Yes/2R 4 | 36 | No | UD/>800 | Yes/EVR and EFV | Alive |
[27] | 2011/Italy | M/42 | Dilated CM | NR | NR | No | 19 | NR | NR | NR | Alive |
[28]5 | 2000–2016/14 sites USA and Europe | 15 M and 6 F/27–61 | Non-ischemic CM: 17; ischemic CM: 4 | INSTI-based: 8 PI-based: 4 NNRTI-based: 8 Other: 1 | FK: 16 CYA: 5 Most received MMF and P | Yes: 14/mild = 6; moderate = 8) | 6-123 (median of 35) | 16 | UD/median of 411 at 1 year | Yes: 4 possible/PI and CNI | Alive (64%) |